Trial Profile
A Phase 1, Randomised, Single Blind, Placebo Controlled, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Farudodstat (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors ASLAN Pharmaceuticals
- 22 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jan 2015 New trial record